Treatment Continuity, Dose Modification, and Real-World Tolerability

The panel discusses the notably low treatment discontinuation rates seen with ADCs in both pivotal trials compared with chemotherapy, and whether these reassuring numbers translate to real-world practice. Panelists frame low discontinuation as a meaningful signal while noting that trial populations, with favorable performance status, protocol-driven monitoring, and strong supportive care, may not fully reflect community patients with more comorbidities and less support. The conversation emphasizes that dose delays and reductions are an expected, acceptable part of keeping patients on effective therapy, and that staying on treatment carries real value for patients in terms of stability and quality of life. Panelists share practical experiences with prophylaxis adherence challenges and the importance of close monitoring and patient communication. The discussion underscores a shared, multidisciplinary responsibility to support patients through proactive prophylaxis and early dose modification. Viewers gain a candid, practice-oriented perspective on optimizing tolerability and treatment continuity.